Mazdutide
玛仕度肽Dual GCG/GLP-1 receptor agonist approved by NMPA for chronic weight management (Jun 2025) and T2D (Sep 2025); added to 2026 NRDL restricted to adult T2D.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字H20250036, 国药准字H20250037, 国药准字H20250038
- Initial Approval Date
- Jun 24, 2025
- Notice Published
- Jun 30, 2025
- MAH
- Innovent Biologics (Suzhou) Co., Ltd. (信达生物制药(苏州)有限公司)
- Approved Scope
- 3 initial presentation(s) & 1 supplemental event(s) verified — see table below.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #30 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Restricted to adults with Type 2 Diabetes mellitus.
- 限成人2型糖尿病患者。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
Approved Products, Dosage Forms & Approval Numbers
4 verified NMPA records| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字H20250036 | Injection (注射液) 0.5ml:2mg / 4mg / 6mg | Supplemental Indication Glycemic control in adults with Type 2 Diabetes mellitus (monotherapy or in combination with oral antidiabetic agents); covers H20250036 / H20250037 / H20250038. 本品适用于成人2型糖尿病患者的血糖控制(单药治疗或联合二甲双胍等口服降糖药)。 | Approved: 2025-09-16 | Innovent Biologics (Suzhou) Co., Ltd. |
| 国药准字H20250036 | Injection (注射液) 0.5ml:2mg | Initial Approval Chronic weight management in adults as an adjunct to diet and physical activity (initial BMI ≥ 28 kg/m² obesity, or BMI ≥ 24 kg/m² overweight with at least one weight-related comorbidity). 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。 | Approved: 2025-06-24 Published: 2025-06-30 | Innovent Biologics (Suzhou) Co., Ltd. |
| 国药准字H20250037 | Injection (注射液) 0.5ml:4mg | Initial Approval Chronic weight management in adults (4 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30). 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。 | Approved: 2025-06-24 Published: 2025-06-30 | Innovent Biologics (Suzhou) Co., Ltd. |
| 国药准字H20250038 | Injection (注射液) 0.5ml:6mg | Initial Approval Chronic weight management in adults (6 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30). 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。 | Approved: 2025-06-24 Published: 2025-06-30 | Innovent Biologics (Suzhou) Co., Ltd. |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Added to Negotiated List
Newly added to 2026 NRDL Negotiated List (#30, Class B, price redacted *); restricted to adults with Type 2 Diabetes mellitus (weight management indication not reimbursed).
Chinese original: 新增纳入2026版谈判药品第30项(乙类,支付标准*),限成人2型糖尿病患者;协议期2027-01-01至2028-12-31。
NHSA · PDF p.119Verified 2026-11-20 - (2025-09-16)NMPA Approval
NMPA Supplemental Indication Approval (国药准字H20250036 · 0.5ml:2mg / 4mg / 6mg)
Glycemic control in adults with Type 2 Diabetes mellitus (monotherapy or in combination with oral antidiabetic agents); covers H20250036 / H20250037 / H20250038.
Chinese original: 本品适用于成人2型糖尿病患者的血糖控制(单药治疗或联合二甲双胍等口服降糖药)。
MAH · PDF p.3 (T2D Label)Verified 2026-11-20 - (2025-06-24)NMPA Approval· Notice published: Jun 30, 2025
NMPA Initial Marketing Approval (国药准字H20250036 · 0.5ml:2mg)
Chronic weight management in adults as an adjunct to diet and physical activity (initial BMI ≥ 28 kg/m² obesity, or BMI ≥ 24 kg/m² overweight with at least one weight-related comorbidity).
Chinese original: 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。
NMPA · NMPA Delivery Notice 2025-06-30Verified 2026-11-20 - (2025-06-24)NMPA Approval· Notice published: Jun 30, 2025
NMPA Initial Marketing Approval (国药准字H20250037 · 0.5ml:4mg)
Chronic weight management in adults (4 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).
Chinese original: 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。
NMPA · NMPA Delivery Notice 2025-06-30Verified 2026-11-20 - (2025-06-24)NMPA Approval· Notice published: Jun 30, 2025
NMPA Initial Marketing Approval (国药准字H20250038 · 0.5ml:6mg)
Chronic weight management in adults (6 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).
Chinese original: 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。
NMPA · NMPA Delivery Notice 2025-06-30Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- MAHPublished 2025-09-16玛仕度肽注射液说明书(信达生物)Retrieved 2026-11-20
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NMPAPublished 2025-06-30国家药监局药品批准证明文件送达信息(2025年06月30日)Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20